Microvesicles and their role in cardiovascular pathology

In recent years, there has been a tendency to increase the number of acute myocardial infarctions (AMI) in young people. The search and study of risk factors (FR), pathogenetic mechanisms of cardiovascular complications (CVD) and methods of targeted exposure continues. One of the mechanisms of MTR is the pathology of the hemostasis system-. vascular-platelet (microvesicles), coagulation hemostasis (thrombin, tissue factor\tissue factor inhibitor) and fibrinolysis systems (coagulation factor II and XIII), an imbalance of which can lead to vascular catastrophes. In recent decades, microvesicles of various origins have been studied with precision. Microvesicles are found in the blood normally, but in vascular catastrophes their number increases significantly in the first hours of developing pathology. To assess the quantity and quality of microvesicles may allow timely initiation of therapy, which will lead to a decrease in the focus of ischemia and the development of various early and long-term complications. Normally, microvesicles act as protectors, and their increase occurs in pathological processes. An increase in the concentration of microvesicles of various natures (leukocyte, platelet, erythrocyte) has been studied in oncology, obstetrics and gynecology, as well as in cardiovascular pathology. The determination of microvesicles in the blood can allow stratification of patients into high-risk groups, will allow early therapy to begin. The study of the hemostasis system, especially individual components (microvesicles), allows us to gain new knowledge about the mechanisms of AMI development in the absence of traditional risk factors, to identify prognostically significant biological markers, as well as their concentration, allowing us to predict the risk of coronary events and complications in young patients.